No Data
No Data
Sunflower Pharmaceutical: Semi-Annual Report 2024
Sunflower Pharmaceutical: 2024 Semi-Annual Report Summary
Sunflower Pharmaceutical Group (002737.SZ) released its half-year performance. The net income was 0.486 billion yuan, a decrease of 23.79% compared to the same period last year.
Sunflower Pharmaceutical Group (002737.SZ) released its 2024 interim report, with revenue of 2.527 billion yuan, a year-on-year...
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Shares Lagging The Market But So Is The Business
Sunflower Pharmaceutical Group (002737.SZ): The compound polyethylene glycol (3350) electrolyte oral solution has obtained the approval for listing acceptance.
GeLongHui August 22nd | Sunflower Pharmaceutical Group (002737.SZ) announced that its wholly-owned subsidiary Harbin Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Ha Sunflower") recently received the "Acceptance Notice" for the registration and listing application for electrolyte oral solution of compound polyethylene glycol (3350) issued by the National Medical Products Administration.
Sunflower Pharmaceutical Group (002737.SZ) has a product line led by advantageous varieties such as liver-protecting tablets, stomach Kangling capsules/particles, and mesalazine enteric-coated tablets.
On August 15th, Gelonghui announced that as a leader in adult medicine, Sunflower Pharmaceutical Group's featured areas include treatment for chronic illnesses. With product advantages, the company has formed a segmentation pattern with the digestive system as the dominant category and elderly pain as the core. In terms of the digestive system, the company has a leading product line with liver-protecting tablets, Weikangling capsules/granules, and Mesalazine enteric-coated tablets. The company has extended its product line to cover liver, gallbladder, intestine, and stomach, establishing its product advantages in the field of digestive system medication. In the field of elder pain management, the company is exploring the potential of its existing products.
No Data
No Data